CMBI: Raises Hansoh Pharmaceutical (03692.HK) Target Price to HK$50.54; Roche Collaboration and ESMO Data Reinforce ADC Value

Zhitong Finance APP has learned that CMBI has issued a research report stating that Hansoh Pharmaceutical's (03692.HK) ADC platform has received important validation in both collaboration and clinical aspects. The bank reiterates its "Buy" rating and raises its target price from HK$49.12 to HK$50.54.